Roflumilast: Perbedaan antara revisi

'''Roflumilast''' adalah obat yang digunakan untuk mengobati [[penyakit paru obstruktif kronik]],<ref name="Daliresp FDA label" /> [[psoriasis]] plak,<ref name="Zoryve cream FDA label" /> [[dermatitis seboroik]],<ref name="Zoryve foam FDA label" /> dan [[dermatitis atopik]].<ref name="Zoryve cream FDA label" /> Obat ini bekerja sebagai penghambat enzim fosfodiesterase-4 (PDE-4) yang selektif dan bekerja lama. Obat ini memiliki efek [[antiinflamasi]].<ref name="pmid18044684">{{cite journal | vauthors = Boswell-Smith V, Spina D | title = PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast | journal = International Journal of Chronic Obstructive Pulmonary Disease | volume = 2 | issue = 2 | pages = 121–9 | year = 2007 | pmid = 18044684 | pmc = 2695611 | url = }}</ref><ref name="pmid18307529">{{cite journal | vauthors = Herbert C, Hettiaratchi A, Webb DC, Thomas PS, Foster PS, Kumar RK | title = Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma | journal = Clinical and Experimental Allergy | volume = 38 | issue = 5 | pages = 847–56 | date = May 2008 | pmid = 18307529 | doi = 10.1111/j.1365-2222.2008.02950.x | s2cid = 19050454 }}</ref><ref name="pmid18447606">{{cite journal | vauthors = Field SK | title = Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma | journal = Expert Opinion on Investigational Drugs | volume = 17 | issue = 5 | pages = 811–8 | date = May 2008 | pmid = 18447606 | doi = 10.1517/13543784.17.5.811 | s2cid = 73241684 }}</ref>

Obat ini disetujui untuk penggunaan medis di [[Uni Eropa]] pada tahun 2010,<ref name="Daxas EPAR">{{cite web | title=Daxas EPAR | website=[[European Medicines Agency]] | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/daxas | access-date=28 September 2020 | archive-date=12 August 2020 | archive-url=https://web.archive.org/web/20200812193907/https://www.ema.europa.eu/en/medicines/human/EPAR/daxas | url-status=live }}</ref> di Amerika Serikat pada tahun 2011,<ref name="Daliresp FDA label">{{cite web | title=Daliresp- roflumilast tablet | website=DailyMed | date=12 March 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf | access-date=28 September 2020 | archive-date=25 March 2021 | archive-url=https://web.archive.org/web/20210325081719/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf | url-status=live }}</ref> dan di Kanada pada tahun 2017.<ref name="Daxas CA PI">{{cite web | title=Daxas Product information | website=[[Health Canada]] | date=20 July 2017 | url=https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84447 | access-date=13 July 2024}}</ref> Obat ini tersedia sebagai [[obat generik]].<ref>{{cite web | title=2022 First Generic Drug Approvals | website=U.S. [[Food and Drug Administration]] (FDA) | date=3 March 2023 | url=https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2022-first-generic-drug-approvals | archive-url=https://web.archive.org/web/20230630003602/https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2022-first-generic-drug-approvals | archive-date=30 June 2023 | url-status=live | access-date=30 June 2023}}</ref>